Farewell To Forbes: No, I Am Not Dr Oz, Nor Was Meant To Be

Note to readers: The following post was just published on Forbes. As it explains, the content published here will no longer run simultaneously on Forbes.  In case there’s any confusion: I am no Dr. Oz. I am not fantastically good looking, despite what my mother says. I’m not a cardiac surgeon and, of course, I don’t have a wildly popular…

Click here to continue reading…

Prevalence Of Cardiovascular Disease Likely To Increase Despite Gains In Treatment

It is the best of times and the worst of times in the battle against cardiovascular disease. On the one hand, mortality rates from cardiovascular disease in the US have dropped by more than half in the last 30 years, likely due in large part to improvements in treatment for elevated blood pressure and cholesterol…

Click here to continue reading…

Automatic Wireless Monitoring Shows Benefits in Chronic Heart Failure

Following in the wake of studies that failed to find benefits associated with remote wireless monitoring of heart failure (HF) patients, the In-Time trial, presented at the European Society of Cardiology meeting in Amsterdam, is the first trial to show that home monitoring of HF patients may be beneficial. Gerhard Hindricks, the coordinating investigator of…

Click here to continue reading…

A Guide To The Raging Debate Over The NIH’s TACT Chelation Trial

(Updated) The publication in JAMA of the NIH’s Trial To Assess Chelation Therapy (TACT) trial has provoked a fascinating debate in the blogosphere. The vast majority of responsible physicians and healthcare professionals have little interest in chelation therapy per se, but the TACT trial has raised many important questions about the nature of medical evidence. Here’s a brief…

Click here to continue reading…

A Time For Change: A Letter To Readers

change

CardioBrief is four years old this month. It’s time for change. Starting now, the news and commentary that in the past appeared here on CardioBrief.Org will appear on my section of the Forbes website. I will continue to cover the major cardiology-related news for an audience of healthcare professionals. There will be no major changes…

Click here to continue reading…